K Number
K223161
Device Name
OXY-1 System
Manufacturer
Date Cleared
2023-02-23

(139 days)

Product Code
Regulation Number
870.4350
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The OXY-1 System is intended to be used for extracorporeal circulation. The OXY-1 System pumps, oxygenates and removes carbon dioxide from blood during cardiopulmonary bypass up to 6 hours in duration.
Device Description
The Abiomed OXY-1 System provides extracorporeal circulation for cardiopulmonary bypass support for up to six hours in duration. The OXY-1 System includes: - A Disposable pump and oxygenator . - A Pump Driver (blood pump) ● - Blood tubing . - A Console for controlling the pump and managing gas flow . These components are designed to operate together, simplify operation, and reduce the overall equipment footprint at the bedside.
More Information

Not Found

No
The summary describes a mechanical system for extracorporeal circulation with no mention of AI or ML in the intended use, device description, or performance studies.

Yes
The device is described as supporting "cardiopulmonary bypass," which is a medical procedure used to temporarily take over the function of the heart and lungs during surgery, thus directly treating a physiological process to support life.

No
The stated intended use of the OXY-1 System is for extracorporeal circulation to pump, oxygenate, and remove carbon dioxide from blood during cardiopulmonary bypass. This describes a therapeutic, rather than a diagnostic, function.

No

The device description explicitly lists multiple hardware components including a disposable pump and oxygenator, a pump driver, blood tubing, and a console. This indicates it is a system with significant hardware components, not a software-only device.

Based on the provided information, the OXY-1 System is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use clearly states "extracorporeal circulation" and "pumps, oxygenates and removes carbon dioxide from blood during cardiopulmonary bypass." This describes a device that directly interacts with and supports the patient's circulatory system, not a device used to test samples of blood or other bodily fluids outside the body to diagnose or monitor a condition.
  • Device Description: The components listed (pump, oxygenator, tubing, console) are all consistent with a system used for extracorporeal circulation, not for performing diagnostic tests on samples.
  • Lack of IVD Characteristics: There is no mention of analyzing samples, reagents, or any of the typical components or processes associated with in vitro diagnostics.

Therefore, the OXY-1 System falls under the category of a therapeutic or life support device, not an in vitro diagnostic device.

N/A

Intended Use / Indications for Use

The OXY-1 System is intended to be used for extracorporeal circulation. The OXY-1 System pumps, oxygenates and removes carbon dioxide from blood during cardiopulmonary bypass up to 6 hours in duration.

Product codes

DTZ, KFM, DWA, DWF

Device Description

The Abiomed OXY-1 System provides extracorporeal circulation for cardiopulmonary bypass support for up to six hours in duration. The OXY-1 System includes:

  • A Disposable pump and oxygenator .
  • A Pump Driver (blood pump) ●
  • Blood tubing .
  • A Console for controlling the pump and managing gas flow .
    These components are designed to operate together, simplify operation, and reduce the overall equipment footprint at the bedside.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Not Found

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

K200109

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 870.4350 Cardiopulmonary bypass oxygenator.

(a)
Identification. A cardiopulmonary bypass oxygenator is a device used to exchange gases between blood and a gaseous environment to satisfy the gas exchange needs of a patient during open-heart surgery.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Guidance for Cardiopulmonary Bypass Oxygenators 510(k) Submissions.”

0

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA acronym with the full name of the agency on the right. The FDA part of the logo is in blue, with the acronym in a square and the full name written out to the right of the square.

February 23, 2023

Abiomed Inc. Ken Ryder Sr. Director, Regulatory Affairs 22 Cherry Hill Drive Danvers, Massachusetts 01923

Re: K223161

Trade/Device Name: OXY-1 System Regulation Number: 21 CFR 870.4350 Regulation Name: Cardiopulmonary Bypass Oxygenator Regulatory Class: Class II Product Code: DTZ, KFM, DWA, DWF Dated: January 25, 2023 Received: January 27, 2023

Dear Ken Ryder:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for

1

devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely.

Nicole M. Gillette -S

Nicole Gillette Assistant Director DHT2B: Division of Circulatory Support, Structural and Vascular Devices OHT2: Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

2

Indications for Use

510(k) Number (if known) K223261

Device Name OXY-1 System

Indications for Use (Describe)

The OXY-1 System is intended to be used for extracorporeal circulation. The OXY-1 System pumps, oxygenates and removes carbon dioxide from blood during cardiopulmonary bypass up to 6 hours in duration

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 201 Subpart D)Over-The-Counter Use (21 CFR 300)
-------------------------------------------------------------------------------------------------------------------------------------------

X Prescription Use (Part 21 CFR 801 Subpart D)

| | Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

3

Abiomed OXY-1 System 510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the Safe Medical Devices Act (SMDA) of 1990 and Title 21 of the Code of Federal Regulations, Part 807.92.

A. Application Information:

Date Prepared:October 06, 2022
Submitter's Name & Address:ABIOMED, Inc.
22 Cherry Hill Drive
Danvers, MA 01923
Contact Person:J. Kenneth Ryder
Senior Director, Global Regulatory Affairs
Ph: 978-646-1707
E-mail: kryder@abiomed.com

B. Device Information:

Trade or Proprietary Name:OXY-1 System
Common or Usual Name:OXY-1 System
FDA Classification:Class II, 21 CFR 870.4350
Regulation Description:Cardiopulmonary bypass oxygenator
Product Code:DTZ - Oxygenator, Cardiopulmonary Bypass
KFM - Pump, Blood, Cardiopulmonary Bypass, Non-Roller
Type
DWA - Control, Pump Speed, Cardiopulmonary Bypass
DWF - Catheter, Cannula and Tubing, Vascular,
Cardiopulmonary Bypass

C. Predicate Device:

The primary predicate device was the OXY-1 System, which is cleared under K200109.

D. Device Description:

The Abiomed OXY-1 System provides extracorporeal circulation for cardiopulmonary bypass support for up to six hours in duration. The OXY-1 System includes:

  • A Disposable pump and oxygenator .
  • A Pump Driver (blood pump) ●
  • Blood tubing .
  • A Console for controlling the pump and managing gas flow .

These components are designed to operate together, simplify operation, and reduce the overall equipment footprint at the bedside.

4

E. Indications for Use:

INDICATIONS FOR USE:

The OXY-1 System is intended to be used for extracorporeal circulation. The OXY-1 System pumps, oxygenates and removes carbon dioxide from blood during cardiopulmonary bypass up to 6 hours in duration.

F. Technological Characteristics Comparison of Subject and Predicate Devices:

The subject device, the OXY-1 System (Configuration 2) is identical to the predicate device Intended Use/Indications for Use, general system components, sterilization, and mechanism of action. Differences between the subject device and the predicate device were all determined to be minor, have no adverse impact on safety or effectiveness, and raise no different questions of safety or effectiveness compared to the predicate device. The minor differences include the oxygenator effective surface area and the presence of a green indicator light on the pump driver.

Subject DevicePredicate Device
Technological
CharacteristicsOXY-1 System (Configuration 2)OXY-1 System (Configuration 1)
Oxygenator
MembranePolymethylpentenePolymethylpentene
HousingPolycarbonatePolycarbonate
PottingUrethaneUrethane
Heat ExchangerNoNo
Membrane TypeHollow FiberHollow Fiber
Effective Membrane
Surface Area2.3 m²2.4 m²
Gas PathwayTwo Gas PathwaysTwo Gas Pathways
Oxygenator GeometryCylindricalCylindrical
Tubing Connectors3/8"3/8"
Priming Volume
(Oxygenator Only)285 ml285 ml
SterileSAL 10^-6SAL 10^-6
Sterilization methodEthylene OxideEthylene Oxide
Performance Specifications (Oxygenator)
Blood Flow Rate0.5-5.0 Lpm0.5-5.0 Lpm
Gas TransferTested per "Guidance for
Cardiopulmonary Bypass
Oxygenators 510(k) Submissions"
Dated November 13, 2000Tested per "Guidance for
Cardiopulmonary Bypass
Oxygenators 510(k) Submissions"
Dated November 13, 2000
HemolysisAverage NIH of 0.0210 mg/100LAverage NIH of 0.0210 mg/100L
Pressure Drop (at 5 Lpm)Average of 38 mmHgAverage of 38 mmHg
CouplingMagneticMagnetic
Energy SourceBattery / MainsBattery / Mains
Other Features
Sweep Gas SourceInternal / ExternalInternal / External
Sighing Gas SourceInternal / ExternalInternal / External
Software
Constant RPM ModeYesYes
Constant Flow ModeNoNo
User Interface/ Display
Blood FlowYesYes
Pump RPM SettingsYesYes
Internal Sweep GasYesYes
Alarm Limit SettingsYesYes
Blood FlowYesYes
BubbleYesYes
Low BatteryYesYes
System Failure AlarmsYesYes
Bubble SensorYesYes
Pump Driver
LED Indicator LightYesNo
Controller & Driver
Flow SensorYesYes
Emergency Drive UnitHand CrankHand Crank
RPM Range0-4500 RPM0-4500 RPM
Blood Tubing
TubingPolyvinyl ChloridePolyvinyl Chloride

5